Tabsamo Group is built as a holding company, not a single product. The thesis is simple: a family of institutions, each run on its own terms, shares more than a product line ever could — a standard for how things are built, a bar for how long they should last, and a refusal to treat any one market as a side quest.
A single product chasing many markets dilutes. Each new market pulls the roadmap in a different direction, and the product slowly becomes the average of everything it tried to be. Ventures under one discipline do the opposite: each stays sharp in its own market, while the things that are genuinely shared — identity, payments, design, the engineering bar — get better for everyone at once.
That is why the work is organised as separate institutions rather than features of one app. eHR can be civic and careful because it is not also trying to be a marketplace. Bila can obsess over payment reliability because it is not also a clinical record. Baacil can take the long, patient view of research because it is not on a commercial release cadence. Focus is preserved where it matters, and only the foundation is held in common.
Compounding is the point. A shared identity layer that improves once improves for every venture. A payment integration hardened in one product is available to the next. A design decision made well is inherited rather than re-litigated. Ten teams making the same mistake is waste; one institution making a decision once and reusing it is leverage.
It is also how risk is carried. No single venture has to be the whole company. Some will move fast, some will incubate for years, and the portfolio absorbs the variance that would sink a one-product company. The discipline is the constant; the ventures are free to be different.